At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 137 enrolled
Drug / intervention
Placebo - Cap +1 moredrug
Likely dose
Amiloride Pill 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Estrogen Receptor Alpha Signaling in Endothelial Cells Exacerbates Arterial Stiffening Via Upregulation of ENaC in Insulin Resistant Females
In Brief
A Phase 3 clinical trial evaluating Placebo - Cap and Amiloride Pill for Overweight and Obesity and Insulin Resistance. Completed, enrolled 137 participants across 1 site.
Detailed Summary
To determine whether treatment with the ENaC inhibitor, amiloride, improves endothelial function and arterial stiffness in obese insulin resistant subjects in a randomized placebo-controlled trial examining pre and postmenopausal women and age-matched men.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight and Obesity, Insulin Resistance
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartJul 2019
Primary CompletionOct 2024
Study CompletionApr 2025
TodayJul 2026
First PostedFeb 12, 2019
Enrollment StartJul 15, 2019
Primary CompletionOct 5, 2024
Study CompletionApr 30, 2025
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 7.4 years ago
Interventions
Placebo - Capdrug
6 months of 1 pill a day
Amiloride Pilldrug
Max dose of 5 mg a day for 6 months